Skip to content

Comparison of Safety and Clinical Effects of Straight and Articulated Instruments (ArtiSential) in Laparoscopic Gastrectomy for Gastric Cancer Patients, a Prospective Randomized Study

Comparison of Safety and Clinical Effects of Straight and Articulated Instruments (ArtiSential) in Laparoscopic Gastrectomy for Gastric Cancer Patients, a Prospective Randomized Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07100431
Enrollment
76
Registered
2025-08-03
Start date
2022-06-22
Completion date
2023-12-31
Last updated
2025-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Adenocarcinoma Patients, Who Are Scheduled for Laparoscopic Radical Gastrectomy

Brief summary

In patients with gastric cancer, gastrectomy can be performed via laparoscopic/robotic or open surgery. It is crucial to completely remove the tumor along with an adequate extent of lymph node dissection. The number of lymph nodes retrieved during gastrectomy is considered an important factor associated with the quality of the surgery and can serve as an indicator of the completeness of the procedure. In particular, during the dissection of lymph node stations 8, 9, 11p and 12a - which are located near the superior aspect of the pancreas - pressure is often applied to the pancreas to secure an adequate surgical view. Recent studies have suggested that this may be associated with postoperative pancreatic complications. It is believed that the use of articulating instruments during laparoscopic gastrectomy may enable a safer dissection of lymph nodes located above the pancreas. However, to date, there have been lack of studies comparing the safety and efficacy of articulating versus straight instruments in laparoscopic gastrectomy. Therefore, this study aims to analyze the compare these two approaches.

Interventions

PROCEDUREArticulating (experimental group)

1\. Surgical procedure On the day of surgery, random allocation to either the experimental or the control group will be perfored just before the start of the procedure. All of the surgery will be conducted laparoscopically. The control group will undergo surgery using a conventional straight laparoscopic instrument, while the experimental group will use an articulating instrument. The surgical procedure will be the same for both groups. The total time of surgery and the time spent on the supra-pancreatic lymph node dissection will be recorded during the procedure. The estimated blood loss during surgery will be also measured.

PROCEDUREControl (control group)

2\. Postoperative follow-up Patients participating in this study will have the same postoperative care as those not participating in this study. To compare the degree of pancreatic injury, amylase and lipase levels will be measured in the serum and the peritoneal fluid frome the drainage on postoperative days 1 and 3. Postoperative complications will be classified and recorded according to the Clavien-Dindo classification for all complications occurring within 30 days after surgery. The dissected lymph nodes will be categorized by region, and the number of dissected lymph nodes will also be confirmed.

Sponsors

Gangnam Severance Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Patients were randomly assigned in a 1:1 ratio to two groups; the control group or the experimental (Articulating) group.

Intervention model description

During supra-pancreatic lymph node dissection, the assistant provides downward traction on the pancreas head with an instrument in their left hand to secure a clear surgical view. In the Control group, a conventional straight laparoscopic instrument was used for this purpose, while in the Articulating group, an articulating laparoscopic instrument (ArtiSential®, LIVSMED, Maryland jaw) was used.

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients diagnosed with gastric adenocarcinoma pathologically before surgery 2. Patients scheduled for laparoscopic radical gastrectomy 3. Patients aged more than 20 4. Patients with an ECOG 0 or 1

Exclusion criteria

1. Patients with a history of gastrectomy 2. Patients with a history of pancreatitis or pancreatic surgery 3. Patients with a history of abdominal surgery who are expected to have severe intra-abdominal adhesions 4. Patients scheduled for total gastrectomy with D2 lymph node dissection

Design outcomes

Primary

MeasureTime frameDescription
The reduction in operative time achieved by using an articulating instrument for dissection of suprapancreatic lymph nodes during laparoscopic gastrectomyDuring surgery, the total operation time, and the supra-pancreatic lymph node dissection time will be calculated respectively. The supra-pancreatic lymph node dissection time will be measured from the point of right gastric artery ligation to just beforeTo confirm that the use of articulating instruments in radical gastrectomy can lead to more efficient and safer surgery compared to conventional straight instruments.

Secondary

MeasureTime frameDescription
The degree of pancreas injury after surgeryAmylase levels will be measured in serum and peritoneal fluid on postoperative day 1 and 3.To confirm that the use of articulating instruments in radical gastrectomy can lead to more efficient and safer surgery compared to conventional straight instruments.
Estimated blood lossEstimated blood loss will be calculated during surgery.To confirm that the use of articulating instruments in radical gastrectomy can lead to more efficient and safer surgery compared to conventional straight instruments.
The number of retrieved lymph nodesThe number of retrieved lymph nodes were counted after surgeryTo confirm that the use of articulating instruments in radical gastrectomy can lead to more efficient and safer surgery compared to conventional straight instruments.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026